首页> 美国卫生研究院文献>Journal of Clinical Oncology >Vincristine Actinomycin and Cyclophosphamide Compared With Vincristine Actinomycin and Cyclophosphamide Alternating With Vincristine Topotecan and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Childrens Oncology Group Study D9803

【2h】

Vincristine Actinomycin and Cyclophosphamide Compared With Vincristine Actinomycin and Cyclophosphamide Alternating With Vincristine Topotecan and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Childrens Oncology Group Study D9803

机译：长春新碱放线菌素和环磷酰胺与长春新碱放线菌素和环磷酰胺与长春新碱托泊替康和环磷酰胺交替治疗中度横纹肌肉瘤的比较：儿童肿瘤学小组研究D9803

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThe purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that of patients treated with VAC alternating with vincristine, topotecan, and cyclophosphamide (VAC/VTC).

机译：目的本研究的目的是比较接受标准VAC（长春新碱，放线菌素和环磷酰胺）化疗的中度风险横纹肌肉瘤（RMS）患者与接受长春新碱，托泊替康和环磷酰胺（VAC）交替治疗的VAC患者的结局/ VTC）。

著录项

期刊名称 Journal of Clinical Oncology
作者
Carola A.S. Arndt; Julie A. Stoner; Douglas S. Hawkins; David A. Rodeberg; Andrea A. Hayes-Jordan; Charles N. Paidas; David M. Parham; Lisa A. Teot; Moody D. Wharam; John C. Breneman; Sarah S. Donaldson; James R. Anderson; William H. Meyer;
展开▼
作者单位

展开▼
年(卷),期 -1(27),31
年度 -1
页码 5182–5188
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. [J] . Arndt CA, Stoner JA, Hawkins DS Journal of Clinical Oncology . 2009,第31期

机译：长春新碱，放线菌素和环磷酰胺与长春新碱，放线菌素和环磷酰胺与长春新碱，托泊替康和环磷酰胺交替治疗中度危险性横纹肌肉瘤：儿童肿瘤学研究D9803。
2. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group [J] . Hawkins Douglas S., Chi Yueh-Yun, Anderson James R., Journal of Clinical Oncology . 2018,第27期

机译：向中间瘤和环磷酰胺添加血管腺炎和伊替菌甘酰基和环磷酰胺并未改善中间风险rhabdomyosarcoma的结果：儿童肿瘤学群的报告
3. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. [J] . Arndt CA, Hawkins DS, Meyer WH, Pediatric blood & cancer . 2008,第1期

机译：长春新碱/阿霉素/环磷酰胺和依托泊苷/异环磷酰胺与IRS-IV交替治疗中度危险性横纹肌肉瘤的初步研究结果的比较：儿童肿瘤小组的一份报告。
4. EVALUATION OF DOXORUBICIN WITH VINCRISTINE/CYCLOPHOSPHAMIDE CONSOLIDATION PROTOCOL FOR THE TREATMENT OF CANINE HEMANGIOSARCOMA [C] . Rebecca J Ward, Craig A Clifford, Rebecca E Risbon, Annual conference of the Veterinary Cancer Society . 2008

机译：对犬血管瘤治疗甘蓝苷/环磷酰胺固结方案的多柔比星评价
5. Addition of Vincristine and Irinotecan to Vincristine Dactinomycin and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group [O] . Douglas S. Hawkins, Yueh-Yun Chi, James R. Anderson, -1

机译：长春新碱和伊立替康在长春新碱放线菌素和环磷酰胺中的添加不能改善中度横纹肌肉瘤的疗效：儿童肿瘤学小组的一份报告
6. Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803 [O] . Arndt, Carola A.S., Stoner, Julie A., Hawkins, Douglas S., 2009

机译：长春新碱，放线菌素和环磷酰胺与长春新碱，放线菌素和环磷酰胺与长春新碱，托泊替康和环磷酰胺交替治疗中度横纹肌肉瘤的比较：儿童肿瘤学小组研究D9803

Vincristine Actinomycin and Cyclophosphamide Compared With Vincristine Actinomycin and Cyclophosphamide Alternating With Vincristine Topotecan and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Childrens Oncology Group Study D9803

摘要

著录项

相似文献

相关主题

期刊订阅